Thursday, October 29, 2015 6:03:57 PM
Since that was declared on the OTC Disclosure & News Service dated Jun 15, 2015 it follows that the creation of the data contained in these patents were developed by John Bourque in 2014 or earlier.
February 19, 2013, Mr. Bourque added an additional patent to the Bourque Industries patent portfolio. This is an additional armor patent titled Ballistic Strike Plate and Assembly. He and the Company valued the patent at $1,185,000.
Where in the financials has it been stated by Bourque Industries of the conditions that must be met before these shares are fully transferred to John Bourque?
Do the recent financials mention any other conditions of patent development by John Bourque. I ask wondering if the remaining 3 new patents John M. Bourque has applied for over the past year are his property requiring purchase by Bourque Industries?
If so will there be another billion or two more shares authorized by Bourque Industries to acquire these 3 additional patents, not for cash, but valued for sure a million dollars each with payment to John Bourque in common shares issued at the price of $.003 per share?
Golly, not only is Bourque Industries very rich already in their patent valuation, but soon to become richer, all while unable to bring the patents to market to obtain revenues.
Gosh, not only did John Bourque have his puppets at Bourque Industries Board of Directors agree to the valuation John Bourque put on his patents, which must be the case since no independent valuation was done and no personnel at Bourque Industries were allowed by John Bourque to fully understand the patents details simply because they are not enabled and John Bourque refuses to identify the critical steps he keeps secret that are require for Kryron creation.
Quite clearly... (see below)
... it can be viewed that John Bourque has keep Bourque Industries as a Pig in a Poke delivery system.
The posts contained on my (gotmilk) account are my own opinions and are not recommendations or advise to buy or sell any security, stocks or other investments. These posts are for entertainment purposes only and are not considered to be facts or truth.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM